

January 7, 2015



OncoSec Medical to Present at Three Events in January

SAN DIEGO-- OncoSec Medical Inc. (OTCQB: [ONCS](#)), a company developing DNA-based intratumoral cancer immunotherapies, will present at three events in January. The Company's agenda includes a number of high-profile scientific and investment conferences.

Biotech Showcase 2015

Punit Dhillon, President and CEO, will present a corporate overview of the Company at Biotech Showcase 2015, taking place January 12-14, 2015 in San Francisco, CA. The presentation is scheduled to begin at 9:00 AM PT on Tuesday, January 13.

At the time of the presentation, a live webcast will be available via the following link: <http://edge.media-server.com/m/p/y67x6cc4>.

OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available for 90 days in the "Events" section of the OncoSec web page at <http://www.oncosec.com>.

Biotech Showcase™ provides biotechnology and life sciences companies with an opportunity to present to and meet with investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. For more information, please visit: <http://www.ebdgroup.com/bts/index.php>

An Introspective on Immunotherapy

OncoSec Medical will host "An Introspective on Immunotherapy: A Symposium on Intratumoral Therapy" on Tuesday, January 13 at the Palace Hotel in San Francisco, CA at 5:00 PM PT. The symposium will feature several key opinion leaders discussing the rationale and potential of intratumoral immunotherapy, and OncoSec's role as a leader in this field.

After the symposium has concluded, a webcast will be made available via the following link: www.oncosec.com/jmp-immunotherapy-symposium-2015/

For more information or to RSVP, please contact Jordyn Kopin, Associate Director of Corporate Communications: jkopin@oncosec.com

Noble Financial Capital Markets 11th Annual Investor Conference

Jordyn Kopin, Associate Director of Corporate Communications, will present a corporate overview of the Company at Noble Financial Capital Markets' 11th Annual Investor Conference. The conference will be held January 18-21, 2015 at Club Med, Sandpiper Bay,

FL. For more information, please visit: <http://www.nobleresearch.com/D2/2015.htm>

About OncoSec Medical

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:

OncoSec Medical Inc.

Jordyn Kopin, 855-662-6732

investors@oncosec.com

or

Public Relations:

Dian Griesel Int'l.

Laura Radocaj, 212-825-3210

lradocaj@dgicomm.com

Source: OncoSec Medical Inc.